Jubilant DraxImage Inc. (DraxImage), a subsidiary of Jubilant Life Sciences and Cyclopharm Limited (CYC), provider of innovative solutions in nuclear medicine signed a term sheet to market and distribute Technegas in the United States. DraxImage will assist CYC with the development and financing of the phase III clinical trials for Technegas, and any other steps required to file for and obtain US FDA approval.
Biocon Ltd. Asia's premier biopharmaceuticals company, inaugurated a world class facility for manufacturing new generation, patient-friendly devices for its insulins portfolio. The facility was inaugurated by Mr. Amitabh Kant, Secretary, Department of Industrial Promotion and Policy, Govt. of India along with Mr. Kaushik Mukherjee, Chief Secretary, Government of Karnataka and Ms. V. Manjula, Secretary, IT,BT and S&T, Government of Karnataka. Mr Kant also launched Basalog One™, a high-end, ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes, manufactured in this facility.
Dr. Reddy’s Laboratories signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze™ Lotion. The exclusive rights for this product are applicable for the territories of the United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.
[adsense:336x280:8701650588]
AstraZeneca, a global, innovation-driven biopharmaceutical business, and The University of Manchester, a member of the prestigious Russell Group of British universities collaborate to deliver personalised healthcare for cancer patients. The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time. As part of the collaboration, AstraZeneca will provide a total of £11.5 million.
(Business Wire India); A clinical study conducted on 50 women in the age group of 18-45 years showed significant results in the treatment of polycystic ovary syndrome with the use of Fenugreek seed extract (Furocyst). The average BMI of the study population was 23.88 and had adequate hepatic, renal and haematological functions. At the time of enrolment, most of the patients had prolonged menstrual cycle (81%) and a few had irregular cycle (10%). Rest of the patients (10%) had primary infertilities.
[adsense:336x280:8701650588]
Bausch & Lomb launch Obagi’s blockbuster products like Thermage, Fraxel, Vaser & Clear + Brilliant and few more offerings in the pipeline. This strategic move of expanding in the premium skincare segment, would further strengthen Bausch & Lomb’s position in the INR 285 - 290 billion beauty care market, growing at a rate 15 to 20 per cent per annum (As per FICCI Wellness Report 2013).
Kraft Heinz Company's Indian affiliate Kraft Heinz India which is a food and beverage major With partnership with Stop Hunger Now, a non-profit organisation, and Society for Action in Community has launched a mobile medical unit (MMU) service in Kalajore village in Bihar, the company release stated.
The Indian Patent Office has rejected American drug maker Pfizer's patents for its rheumatoid arthritis drug tofacitinib in India.
“After having considered the submissions submitted by the applicant (Pfizer) in the hearing, the written submission and amended claims filed as well as in view of the discussions and findings by me, it is hereby ordered that the invention disclosed and claimed in the instant application is not considered as an invention under the provisions of the Act”, said Bharat N S, assistant controller of patents & designs, Mumbai.
(Business Wire India); RWL Healthworld Ltd. (formerly known as Religare Wellness) has been re-branded as Fortis Health World; and is successfully running a leading e-commerce portal that sells beauty, wellness and health-care products such as baby care products, face and skin care range, home and living utilities as well as diabetic remedies.
Mumbai based pharma major Lupin Limited announced that its subsidiary Lupin Pharmaceuticals Inc (Lupin) has launched its Duloxetine 40 mg delayed-release (DR) capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
